Response and Safety of Cetuximab Administration as First Line Therapy in Patients with Unresectable Squamous Cell Skin Carcinoma: A Retrospective Chart Review

Print this page

Response and Safety of Cetuximab Administration as First Line Therapy in Patients with Unresectable Squamous Cell Skin Carcinoma: A Retrospective Chart Review

To document the cetuximab experience in this patient population which represents an unmet need and use this information as a reference point to begin to design future studies.
-to describe that cetuximab with or without chemotherapy is well tolerated among patients with advanced and unresectable squamous cell carcinoma and will show preliminary efficacy that should be explored in future, randomized studies.

Protocol Number091305
Principal InvestigatorJanice Mehnert
ScopeNational
Applicable Disease SitesMelanoma, skin
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.